Protein folding

With Over a Million TPS, Can Primelab Make Web3 a Reality and Replace Web2?

Retrieved on: 
Friday, September 2, 2022
Bitcoin, Communication, Post-silicon validation, Blockchain, Computer, TPS, Steroid, Smartphone, Ecosystem, Protein folding, MacBook Pro, Mechanics, Protein, Cryptocurrency

At over 100x faster than any current blockchain, PrimeLab is a decentralized ecosystem on steroids, that anyone can validate.

Key Points: 
  • At over 100x faster than any current blockchain, PrimeLab is a decentralized ecosystem on steroids, that anyone can validate.
  • TPS speed breakthroughs we're a multi-component utilizing a new encoding method that eliminates bottlenecks in current blockchain transaction handling.
  • The network hosts entire Web2 & Web3 applications on globally distributed virtual machines allocated to end users by the blockchain.
  • Web3 hosting is achieved by a blockchain network built on multiple, novel consensus mechanisms including "proof of usage" & "proof of utility."

Global Artificial Intelligence Computing Software Market Report 2022: A $37.6 Billion Market in 2026

Retrieved on: 
Tuesday, July 26, 2022
DL, Acquisition, Investment, ASIC, Application-specific integrated circuit, Industry, Parity, Protein folding, CPU, Research, ML, Solution, FPGA, Workforce, Edge, Deep learning, Graphics processing unit, Adoption, Machine learning, Intelligence, Technology, Physics, Industrial internet of things, Neuromorphic engineering, RPA, GPU, Growth, Workflow, Industrial, Decision-making, AI, Field-programmable gate array, Medical device, Video game console, Renewable energy, Cryptocurrency

DUBLIN, July 26, 2022 /PRNewswire/ --The "Artificial Intelligence Computing Software: Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 26, 2022 /PRNewswire/ --The "Artificial Intelligence Computing Software: Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Market is predicted to grow from $ 6.9B in 2021 to $ 37.6B in 2026 and may become a new sector of the economy.
  • This comprehensive analysis can aid you in your technology acquisitions or investment decisions related to the fast-growing AI processors market.
  • As machine learning entered exponential growth, it expanded into areas usually dominated by high-performance computing - such as protein folding and many-particle interactions.

Artificial Intelligence Computing Software Market Analysis Report 2022: Complete Information of the AI-related Processors Specifications and Capabilities by Key Market Players and Start-ups. - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022
Software, Technology, Artificial Intelligence, DL, Acquisition, Investment, ASIC, Application-specific integrated circuit, Industry, Parity, Protein folding, CPU, Research, ML, Solution, FPGA, Workforce, Edge, Deep learning, Graphics processing unit, Adoption, Machine learning, Intelligence, Technology, Physics, Industrial internet of things, Neuromorphic engineering, RPA, GPU, Growth, Workflow, Industrial, Decision-making, AI, Field-programmable gate array, Medical device, Video game console, Renewable energy, Cryptocurrency

The "Artificial Intelligence Computing Software: Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artificial Intelligence Computing Software: Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • This research contains complete information of the AI-related processors specifications and capabilities which were produced by the key market players and start-ups.
  • This comprehensive analysis can aid you in your technology acquisitions or investment decisions related to the fast-growing AI processors market.
  • As machine learning entered exponential growth, it expanded into areas usually dominated by high-performance computing - such as protein folding and many-particle interactions.

Phaidra Uses AI to Boost Industrial Profitability and Reduce Emissions

Retrieved on: 
Friday, July 15, 2022
Learning, Climate change, Energy Vault, Power, COVID-19, CEO, Flying fish, JCI, Solution, Artificial intelligence, HVAC, Google, Technology, AI, Human, CTO, Industry, Efficiency, Growth, Climate, Protein folding, DeepMind, Character, Management, Milk, Renewable energy, AlphaGo, Phaedra, Shield

The $25M Series A will help Phaidra accelerate its mission of increasing Fortune 100 profitability while reducing emissions with artificial intelligence and deep reinforcement learning.

Key Points: 
  • The $25M Series A will help Phaidra accelerate its mission of increasing Fortune 100 profitability while reducing emissions with artificial intelligence and deep reinforcement learning.
  • We started Phaidra to bring the benefits of this technology beyond the tech companies to the industrial sector," said Jim Gao, CEO of Phaidra.
  • Phaidra's AI platform enables the industrial sector to radically improve resource efficiency via self-learning control systems.
  • This increases profitability, efficiency, and process stability for Phaidra's industrial customers while reducing emissions.

LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis

Retrieved on: 
Wednesday, June 8, 2022
Achievement, Research, CFPS, LinkedIn, Thomas Jefferson National Accelerator Facility, Technology, EU, Protein folding, Adoption, Glycosylation, Industry, Alice, Protein, Fine chemical, Vaccine

This offers a significant step forward in eukaryotic protein expression.

Key Points: 
  • This offers a significant step forward in eukaryotic protein expression.
  • CFPS systems offer a number of benefits over cell-based protein alternatives, including shorter protein production time (hours vs. months), and the ability to produce proteins at levels usually toxic to living cells.
  • LenioBio will be exhibiting within the European Innovation Council Pavilion (Hall C, booth #1911) at the 2022 BIO International Convention, June 13-16.
  • LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

LenioBio reaches industrial-scale with its high-yield eukaryotic platform for cell-free protein synthesis

Retrieved on: 
Wednesday, June 8, 2022
Achievement, Research, CFPS, LinkedIn, Thomas Jefferson National Accelerator Facility, Technology, EU, Protein folding, Adoption, Glycosylation, Industry, Alice, Protein, Fine chemical, Vaccine

This offers a significant step forward in eukaryotic protein expression.

Key Points: 
  • This offers a significant step forward in eukaryotic protein expression.
  • CFPS systems offer a number of benefits over cell-based protein alternatives, including shorter protein production time (hours vs. months), and the ability to produce proteins at levels usually toxic to living cells.
  • LenioBio will be exhibiting within the European Innovation Council Pavilion (Hall C, booth #1911) at the 2022 BIO International Convention, June 13-16.
  • LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell.

EtiraRx's Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials

Retrieved on: 
Thursday, June 2, 2022
Endoplasmic reticulum stress in beta cells, Cell death, CEO, Glioblastoma, ER, Therapeutic index, Patient, DRS, Protein folding, LIPA, Heel, Endoplasmic reticulum, Achilles, Vaccine, Pharmaceutical industry, DALLAS, List of Nature Research journals

DALLAS, June 2, 2022 /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers. EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.

Key Points: 
  • EtiraRx, headquartered in Biolabs Pegasus Park, plans to initiate clinical trials as early as the first quarter of 2023.
  • Jung-Mo Ahn, Ganesh Raj and Ratna Vadlamudi, identified that ERX-41 dramatically enhances endoplasmic reticulum (ER) stress in cancer cells.
  • The study set the foundation for clinical trials with patients with therapy-resistant cancers that are vulnerable to enhanced ER stress.
  • Russell Hayward, CEO EtiraRx, said, "ERX-41 has the potential to be a first-in-class oral therapy that kills aggressive therapy-resistant cancers.

Qumulo Named TOP 5 Rising Storage Vendor for Life Sciences by Leading Technology Research Firm DCIG

Retrieved on: 
Tuesday, May 31, 2022
Data Management, Health, Technology, Software, Networks, Biotechnology, Health, Environment, News, Solution, Research, PACS, SMB, NFS, REST, Organization, Genomics, FTP, Intelligence, Protein folding, CEO, Computer data storage, Video game console, S3, Qumulo

Qumulo , the leader in data storage and management at scale, today announced that DCIG named Qumulo a Top 5 storage vendor in its 2022-2023 DCIG TOP 5 Rising Vendors in Storage for Life Sciences Solutions report.

Key Points: 
  • Qumulo , the leader in data storage and management at scale, today announced that DCIG named Qumulo a Top 5 storage vendor in its 2022-2023 DCIG TOP 5 Rising Vendors in Storage for Life Sciences Solutions report.
  • Life sciences organizations manage huge volumes of data to research and develop life-saving solutions, using powerful processes like genomics sequencing, molecular simulations and protein folding.
  • Qumulo stood out as a storage vendor that can keep up with the rapid pace of scientific discovery.
  • Theres a lot at stake for the life sciences organizations handling the worlds most critical data workloads, said Bill Richter, CEO of Qumulo.

Isomorphic Labs Announces First Phase of Management Team

Retrieved on: 
Thursday, May 12, 2022
Software, Research, Pharmaceutical, Technology, Infectious Diseases, Clinical Trials, Science, Biotechnology, Other Technology, FDA, Other Science, Health, People, Food, The People's Operator, Royal Society, Ontario Institute for Cancer Research, Heidelberg University, Nature, Compliance, Rising Production, University, University of Leicester, Sophia, Breast, Drug discovery, Amazon, Oxford Brookes University, Sophia Genetics, Machine learning, GPCR, Biology, EMBL, DeepMind, Pan-Cancer Analysis, Algorithm, Research, Biophysics, Technical Working Groups, Ribociclib, Mathematics, Royal, AlphaFold, RSC, Google, Chemistry, Doctor of Philosophy, Risk, Science, University of Cambridge, FDA, Toronto, GENETICS, Publication, Engineering, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Deep learning, Technical, Astex, GlaxoSmithKline, G protein-coupled receptor, Drug development, Drug, Protein folding, CEO, Pharmaceutical industry, Medical device, Management, Alphabet, AI

Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.

Key Points: 
  • Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.
  • Isomorphic Labs mission is to use AI and machine learning methods to accelerate and improve the drug discovery process.
  • The new leaders join founder and acting CEO Demis Hassabis, who is currently serving as CEO of both DeepMind and Isomorphic Labs.
  • Isomorphic Labs is a subsidiary of Alphabet that was launched from Alphabets DeepMind in 2021, with headquarters in London.

Quantori Announces Powerful HPC Accelerator to Advance Biopharma R&D

Retrieved on: 
Thursday, May 5, 2022
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Other Science, Research, Software, Nanotechnology, Science, LLC, Computational chemistry, Health, Drug discovery, RNA-Seq, ISCB Senior Scientist Award, List, HPC, Poster, Computing, Environment, Genomics, Cryogenic electron microscopy, Data science, Protein folding, Science, Supercomputer, Conference, Solution, CEO, AI, Social media, Pharmaceutical industry, Facebook

HPC is a breakthrough for biopharma companies to compute vast amounts of data to unlock insights and create value, said Richard Golob, CEO, Quantori.

Key Points: 
  • HPC is a breakthrough for biopharma companies to compute vast amounts of data to unlock insights and create value, said Richard Golob, CEO, Quantori.
  • Quantoris HPC solutions include a new Computation Platform Accelerator for applications in genomics, CHIP-seq and RNA-seq, cell image analysis, CryoEM, and computational chemistry.
  • Quantoris HPC Accelerator provides scientists with a convenient environment for advancing their early-stage research without having to focus on infrastructure, bridging the gap between science and IT, explained Mikhail Serkov, Senior Director, HPC Services, Quantori.
  • For more information on Quantoris HPC Accelerator, see the HPC Poster Presentation online and at the Bio-IT World Conference & Expo, and visit the Quantori website at https://quantori.com/expertise/hpc .